Role of Cytosorb in Left Ventricular Assist Device Implantation
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2022
-
- participants needed
- 60
-
- sponsor
- Imperial College London
Summary
Mechanical circulatory support, specifically implantable continuous flow left ventricular assist device (CF-LVAD) therapy has been established as a viable treatment for rapidly deteriorating patients suffering from end stage heart failure either as bridge or alternative to heart transplantation. However, a large proportion of these patients experience severe complications in the early postoperative period including right ventricular failure or multi organ failure leading to increased mortality. The leading theory explaining these complications involves exaggerated systemic inflammatory response prior to, during and early after CF-LVAD insertion. Among the cytokines IL-6 appears to play a major role. There is increasing demonstration of the efficacy of a cytokine haemoadsorption (HA) technology in attenuating cytokine response and particularly IL-6 in various inflammatory states and emerging data on the safety of the Cytosorb device in routine and complex cardiac surgery.
The study team hypothesizes that Cytosorb treatment is feasible and safe in heart failure patients undergoing LVAD insertion and that it is effective in attenuating IL-6 secretion with benefit in the wider inflammatory and metabolic response to this high-risk surgery.
Description
The principle objectives of this study are:
- To investigate the efficacy of Cytosorb treatment in attenuating perioperative changes in IL-6 during CF-LVAD implantation
- To investigate the feasibility, and safety of Cytosorb treatment during CF-LVAD implantation.
- To pilot the effect of Cytosorb treatment on vasoplegia and organ dysfunction with specific focus on right ventricle failure, liver failure and acute kidney injury (AKI).
- To establish a collaborative biobank of patient's biological samples to allow extensive characterisation of patient phenotype prior to CF-LVAD implantation and their individual inflammatory and metabolic responses to surgery and perioperative management.
Details
| Condition | Heart failure, Congestive Heart Failure, Heart failure, Heart disease, Heart disease, Cardiac Disease, Congestive Heart Failure, Cardiac Disease, cardiac failure, congestive heart disease |
|---|---|
| Treatment | CytoSorb 300 mL device |
| Clinical Study Identifier | NCT04596813 |
| Sponsor | Imperial College London |
| Last Modified on | 26 January 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer